Research
Quantitative Proteomic Analysis Reveals Effects of Epidermal Growth Factor Receptor (EGFR) on Invasion-promoting Proteins Secreted by Glioblastoma Cells*

https://doi.org/10.1074/mcp.M114.040428Get rights and content
Under a Creative Commons license
open access

Glioblastoma multiforme is a highly invasive and aggressive brain tumor with an invariably poor prognosis. The overexpression of epidermal growth factor receptor (EGFR) is a primary influencer of invasion and proliferation in tumor cells and the constitutively active EGFRvIII mutant, found in 30–65% of Glioblastoma multiforme, confers more aggressive invasion. To better understand how EGFR contributes to tumor aggressiveness, we investigated the effect of EGFR on the secreted levels of 65 rationally selected proteins involved in invasion. We employed selected reaction monitoring targeted mass spectrometry using stable isotope labeled internal peptide standards to quantity proteins in the secretome from five GBM (U87) isogenic cell lines in which EGFR, EGFRvIII, and/or PTEN were expressed. Our results show that cell lines with EGFR overexpression and constitutive EGFRvIII expression differ remarkably in the expression profiles for both secreted and intracellular signaling proteins, and alterations in EGFR signaling result in reproducible changes in concentrations of secreted proteins. Furthermore, the EGFRvIII-expressing mutant cell line secretes the majority of the selected invasion-promoting proteins at higher levels than other cell lines tested. Additionally, the intracellular and extracellular protein measurements indicate elevated oxidative stress in the EGFRvIII-expressing cell line. In conclusion, the results of our study demonstrate that EGFR signaling has a significant effect on the levels of secreted invasion-promoting proteins, likely contributing to the aggressiveness of Glioblastoma multiforme. Further characterization of these proteins may provide candidates for new therapeutic strategies and targets as well as biomarkers for this aggressive disease.

Cited by (0)

Author contributions: V.S. and N.D.P. designed research; V.S. and C.C.F. performed research; V.S., U.K., D.S.C., and R.L.M. contributed new reagents or analytic tools; V.S., C.C.F., R.L.M., and N.D.P. analyzed data; V.S., U.K., and N.D.P. wrote the paper.

*

This work was supported by the NIH-NCI Howard Temin Pathway to Independence Award in Cancer Research (R00 CA126184), the Luxembourg Centre for Systems Biomedicine and the Camille Dreyfus Teacher-Scholar Program (NDP). It was also supported with federal funds from the American Recovery and Reinvestment Act (ARRA) funds through National Institutes of Health; from the National Human Genome Research Institute grant No. RC2 HG005805, the National Institute of General Medical Sciences under grant No. R01 GM087221 and 2P50 GM076547/Center for Systems Biology, and US Department of Defense (Award # W81XWH-11–1-0487) (to RM).

This article contains supplemental Fig. S1 and Tables S1 to S5.